Resveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives
Abstract
Benign prostatic hyperplasia (BPH) is a common age-related disorder characterized by progressive prostatic enlargement and lower urinary tract symptoms, yet current medical therapies remain constrained by delayed onset, incomplete efficacy, and treatment-related adverse effects. Resveratrol (Res), a naturally occurring polyphenol, has emerged as a promising candidate for BPH intervention because its pharmacological profile aligns closely with the multifactorial biology of the disease. This review synthesizes current evidence showing that Res may counteract BPH progression through coordinated regulation of several interconnected processes, including abnormal prostate cell proliferation, apoptosis resistance, oxidative stress, chronic inflammation, fibrotic remodeling, and androgen-related signaling. Rather than acting on a single target, Res appears to reshape the pro-hyperplastic microenvironment at multiple levels, providing a mechanistic rationale for its therapeutic potential. However, the available evidence remains predominantly preclinical, and its clinical translation is still limited by poor oral bioavailability, extensive first-pass metabolism, uncertainty regarding the active molecular species in prostate tissue, and the lack of standardized formulations and robust clinical trials. Overall, Res represents a biologically plausible but not yet clinically established strategy for BPH management.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.